132,217 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Danske Bank A S

Danske Bank A S acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 132,217 shares of the medical equipment provider’s stock, valued at approximately $11,383,000. Danske Bank A S owned about 0.07% of Zimmer Biomet at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Dodge & Cox raised its stake in shares of Zimmer Biomet by 1.3% during the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after purchasing an additional 290,676 shares in the last quarter. Vanguard Group Inc. increased its holdings in Zimmer Biomet by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after buying an additional 192,517 shares during the last quarter. BlackRock Inc. acquired a new position in Zimmer Biomet in the second quarter worth approximately $1,344,282,000. State Street Corp raised its position in Zimmer Biomet by 2.3% during the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock valued at $795,814,000 after acquiring an additional 195,214 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after acquiring an additional 2,017,857 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $101.01 on Friday. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $92.64 and a 200-day simple moving average of $91.00. The stock has a market capitalization of $19.27 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 2.69 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on ZBH shares. Royal Bank Of Canada increased their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. UBS Group reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Truist Financial increased their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $104.42.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.